Furthermore, androgen or anti-androgen treatment resulted in a decrease or an increase, respectively, in sensitivity to cisplatin in AR-positive bladder cancer cells, presumably via modulating the activity of a key factor of cisplatin resistance NF-κB [96]. This evidence concerns the gene AR and urinary bladder carcinoma.